The Nasdaq-listed biotechnology firm is raising $425 million for its ETH strategy, joining a parade of penny stocks investing in cryptocurrencies as their business flounders.
Down 99%, biotech firm 180 Life Sciences pivots to crypto with ETH bet
Related posts
ETHZilla moves into onchain housing finance with 15% Zippy acquisition
The Future of Secure Messaging: Why Decentralization Matters
Ether supply squeeze looms with exchanges holding lowest levels since 2015
BitMine buys $199M in Ether as smart money traders bet on ETH decline
Exclusive data from EigenPhi reveals that sandwich attacks on Ethereum have waned
